The FDA on November 20, 2015 approved MEKINISTĀ® and TAFINLARĀ® for use in combination, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test. MEKINISTĀ® and TAFINLARĀ® are products of Novartis Pharmaceuticals Corp.
Other Pages – Bottom Ad
Advertisement
Subscribe
